Molecular Imaging 2017

Management of Prostate Cancer

Localised Disease:

Low risk

Intermediate risk

High risk

cStage ≥T3a or PSA ng/mL >20 or Gleason 8-10

cStage T1-2a & PSA ng/mL <10 & Gleason ≤6

cStage T2b-c or PSA ng/mL 10-20 or Gleason 7

 Active surveillance  Offer radical treatment if progression

 Radical prostatectomy  Radical radiotherapy  Active surveillance

 Radical prostatectomy  Radical radiotherapy ± androgen deprivation therapy ± brachytherapy

if patient does not wish to proceed to radical treatment immediately

Source: NICE UK Updated Jan 2014